story of the week
Personalized Chemotherapy Based on Tumor Marker Decline in Poor Prognosis Germ-Cell Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Personalised Chemotherapy Based on Tumour Marker Decline in Poor Prognosis Germ-Cell Tumours (GETUG 13): A Phase 3, Multicentre, Randomised Trial
Lancet Oncol 2014 Dec 01;15(13)1442-1450, K Fizazi, L Pagliaro, A Laplanche, A Fléchon, J Mardiak, L Geoffrois, P Kerbrat, C Chevreau, R Delva, F Rolland, C Theodore, G Roubaud, G Gravis, JC Eymard, JP Malhaire, C Linassier, M Habibian, AL Martin, F Journeau, M Reckova, C Logothetis, S CulineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.